| Nome |
# |
|
Utilizing next-generation sequencing in the management of multiple myeloma, file dfa8b998-6155-748b-e053-3a05fe0a3a96
|
1.051
|
|
A non-invasive approach to monitor chronic lymphocytic leukemia engraftment in a xenograft mouse model using ultra-small superparamagnetic iron oxide-magnetic resonance imaging (USPIO-MRI), file dfa8b995-df42-748b-e053-3a05fe0a3a96
|
853
|
|
IL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts, file dfa8b997-2341-748b-e053-3a05fe0a3a96
|
637
|
|
Autoimmune cytopenias in chronic lymphocytic leukemia, file dfa8b994-e667-748b-e053-3a05fe0a3a96
|
615
|
|
International Prognostic Score for Asymptomatic Early-stage Chronic Lymphocytic Leukemia, file dfa8b9a2-68f7-748b-e053-3a05fe0a3a96
|
551
|
|
DIS3 mutations in multiple myeloma impact the transcriptional signature and clinical outcome, file dfa8b9a7-3d91-748b-e053-3a05fe0a3a96
|
486
|
|
HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients, file dfa8b98f-53f9-748b-e053-3a05fe0a3a96
|
473
|
|
Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias : implication for MEK-ERK pathway activation, file dfa8b992-9bb2-748b-e053-3a05fe0a3a96
|
473
|
|
Heterogeneity of TP53 Mutations and P53 Protein Residual Function in Cancer: Does It Matter?, file dfa8b9a5-a929-748b-e053-3a05fe0a3a96
|
441
|
|
HETEROGENEOUS CHROMOSOMAL-ABERRATIONS GENERATE 3' TRUNCATIONS OF THE NFKB2/LYT-10 GENE IN LYMPHOID MALIGNANCIES, file dfa8b990-4c49-748b-e053-3a05fe0a3a96
|
409
|
|
Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma, file dfa8b99d-d651-748b-e053-3a05fe0a3a96
|
388
|
|
Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma : in vitro and in vivo evidence, file dfa8b995-42d2-748b-e053-3a05fe0a3a96
|
387
|
|
TP53 dysfunction in chronic lymphocytic leukemia : clinical relevance in the era of B-cell receptors and BCL-2 inhibitors, file dfa8b9a2-a184-748b-e053-3a05fe0a3a96
|
343
|
|
Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature, file dfa8b995-86bd-748b-e053-3a05fe0a3a96
|
332
|
|
Characterization of the t(4;14)(p16.3;q32) in the KMS-18 multiple myeloma cell line, file dfa8b990-16cb-748b-e053-3a05fe0a3a96
|
330
|
|
Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3-year follow-up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials, file ddd2329d-f076-4045-833e-2cf0e86290d0
|
299
|
|
Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma, file dfa8b992-7aa8-748b-e053-3a05fe0a3a96
|
297
|
|
Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and Bcl2A1 as critical target genes, file dfa8b992-9cd0-748b-e053-3a05fe0a3a96
|
292
|
|
A retained transcriptomic profile characterizes CD138+ cells in the short time progression from smoldering to active multiple myeloma, file dfa8b99d-ac5f-748b-e053-3a05fe0a3a96
|
292
|
|
Bone microenvironment cells reveal a different gene expression profiling in multiple myeloma patients as compared to healthy subjects : potential relationship with the bone status, file dfa8b9a5-c2ce-748b-e053-3a05fe0a3a96
|
291
|
|
Predictive value of the CLL-IPI in CLL patients receiving chemo-immunotherapy as first-line treatment, file dfa8b99c-01b8-748b-e053-3a05fe0a3a96
|
284
|
|
Diagnostic role and prognostic significance of a simplified immunophenotypic classification of mature B cell chronic lymphoid leukemias, file dfa8b990-630d-748b-e053-3a05fe0a3a96
|
282
|
|
Predictive value of beta2-microglobulin (beta2-m) levels in chronic lymphocytic leukemia since Binet A stages, file dfa8b98f-7234-748b-e053-3a05fe0a3a96
|
276
|
|
STRUCTURAL AND FUNCTIONAL-CHARACTERIZATION OF THE PROMOTER REGIONS OF THE NFKB2 GENE, file dfa8b990-4c4b-748b-e053-3a05fe0a3a96
|
261
|
|
Constitutive expression of lymphoma-associated NFKB-2/Lyt-10 proteins is tumorigenic in murine fibroblasts, file dfa8b990-4c4d-748b-e053-3a05fe0a3a96
|
257
|
|
Genome-wide analysis of DNA copy number changes in multiple myeloma using high-density SNP arrays, file dfa8b9a5-f8f1-748b-e053-3a05fe0a3a96
|
257
|
|
Multiple myeloma-derived Jagged ligands increases autocrine and paracrine interleukin-6 expression in bone marrow niche, file dfa8b996-efb9-748b-e053-3a05fe0a3a96
|
256
|
|
Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL) : results of a prospective, single-arm multicentre study, file dfa8b990-630a-748b-e053-3a05fe0a3a96
|
252
|
|
Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity, file dfa8b99b-1d6c-748b-e053-3a05fe0a3a96
|
250
|
|
Long non-coding RNAs in normal and malignant hematopoiesis, file dfa8b995-4987-748b-e053-3a05fe0a3a96
|
244
|
|
Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns, file dfa8b995-c24b-748b-e053-3a05fe0a3a96
|
237
|
|
Pathogenicity of in-vivo generated intestinal Th17 lymphocytes is IFNγ dependent, file dfa8b99b-8ac6-748b-e053-3a05fe0a3a96
|
237
|
|
DIS3 depletion in multiple myeloma causes extensive perturbation in cell cycle progression and centrosome amplification, file be2887dc-7ce0-40ac-89e6-c98680ab6041
|
228
|
|
Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma, file dfa8b9a1-9660-748b-e053-3a05fe0a3a96
|
219
|
|
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo, file dfa8b992-5702-748b-e053-3a05fe0a3a96
|
211
|
|
Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia, file dfa8b990-7f80-748b-e053-3a05fe0a3a96
|
208
|
|
The expression pattern of small nucleolar and small cajal body-specific RNAS characterizes distinct molecular subtypes of multiple myeloma, file dfa8b996-9e6a-748b-e053-3a05fe0a3a96
|
208
|
|
Identification of thyroid tumor cell vulnerabilities through a siRNA-based functional screening, file dfa8b993-31be-748b-e053-3a05fe0a3a96
|
204
|
|
A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation, file dfa8b99c-bdf7-748b-e053-3a05fe0a3a96
|
201
|
|
miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma, file dfa8b995-83f6-748b-e053-3a05fe0a3a96
|
198
|
|
Molecular targeting of the PKC-beta inhibitor enzastaurin (LY317615) in multiple myeloma, file dfa8b9a5-c4fb-748b-e053-3a05fe0a3a96
|
197
|
|
IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies, file dfa8b99c-bcf4-748b-e053-3a05fe0a3a96
|
193
|
|
COPZ1 depletion in thyroid tumor cells triggers type I IFN response and immunogenic cell death, file dfa8b9a1-1caa-748b-e053-3a05fe0a3a96
|
189
|
|
Multiple myeloma exploits Jagged1 and Jagged2 to promote intrinsic and bone marrow-dependent drug resistance, file dfa8b99f-c7c7-748b-e053-3a05fe0a3a96
|
187
|
|
Immunoglobulin heavy chain variable region gene (IGHV) and prediction of time to first treatment (TTFT) in patients with chronic lymphocytic leukemia (CLL): Mutational load or mutational status? Analysis of 1003 cases, file dfa8b99b-e8a8-748b-e053-3a05fe0a3a96
|
185
|
|
Molecular and transcriptional characterization of 17P loss in B-cell chronic lymphocytic leukemia, file dfa8b99f-4d96-748b-e053-3a05fe0a3a96
|
185
|
|
Impact of Host Genes and Strand Selection on miRNA and miRNA* Expression, file dfa8b990-9ab2-748b-e053-3a05fe0a3a96
|
182
|
|
Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias, file dfa8b99a-651c-748b-e053-3a05fe0a3a96
|
182
|
|
Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma, file dfa8b9a1-8a49-748b-e053-3a05fe0a3a96
|
182
|
|
Long non-coding RNA NEAT1 shows high expression unrelated to molecular features and clinical outcome in multiple myeloma, file dfa8b99b-a126-748b-e053-3a05fe0a3a96
|
179
|
|
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine. Results of study on 486 cases outside clinical trials, file dfa8b9a6-e47b-748b-e053-3a05fe0a3a96
|
175
|
|
Notch signaling drives multiple myeloma induced osteoclastogenesis, file dfa8b991-52de-748b-e053-3a05fe0a3a96
|
173
|
|
The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA, file dfa8b995-3d59-748b-e053-3a05fe0a3a96
|
173
|
|
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma, file dfa8b9a7-d5c9-748b-e053-3a05fe0a3a96
|
171
|
|
Disentangling the microRNA regulatory milieu in multiple myeloma : integrative genomics analysis outlines mixed miRNA-TF circuits and pathway-derived networks modulated in t(4;14) patients, file dfa8b993-ccd4-748b-e053-3a05fe0a3a96
|
168
|
|
Plasmablastic lymphoma of the stomach : a case report, file dfa8b998-1a79-748b-e053-3a05fe0a3a96
|
163
|
|
A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias, file dfa8b992-f84d-748b-e053-3a05fe0a3a96
|
162
|
|
Homotypic and Heterotypic Activation of the Notch Pathway in Multiple Myeloma-Enhanced Angiogenesis: A Novel Therapeutic Target?, file dfa8b99c-ddab-748b-e053-3a05fe0a3a96
|
162
|
|
Long non-coding RNAs in B-cell malignancies: a comprehensive overview, file dfa8b998-2225-748b-e053-3a05fe0a3a96
|
158
|
|
Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma, file dfa8b995-8b2f-748b-e053-3a05fe0a3a96
|
156
|
|
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents, file dfa8b999-ddf6-748b-e053-3a05fe0a3a96
|
155
|
|
Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia, file dfa8b990-5e66-748b-e053-3a05fe0a3a96
|
154
|
|
Identification of small molecules uncoupling the Notch : Jagged interaction through an integrated high-throughput screening, file dfa8b999-b2b1-748b-e053-3a05fe0a3a96
|
153
|
|
In silico characterization of miRNA and long non-coding RNA interplay in multiple myeloma, file dfa8b997-6cbc-748b-e053-3a05fe0a3a96
|
149
|
|
Assessment of the 4-factor score : Retrospective analysis of 586 CLL patients receiving ibrutinib : A campus CLL study, file dfa8b9a6-9b34-748b-e053-3a05fe0a3a96
|
147
|
|
miR-23b/SP1/c-myc forms a feed-forward loop supporting multiple myeloma cell growth, file dfa8b994-8f1c-748b-e053-3a05fe0a3a96
|
143
|
|
Notch signaling deregulation in multiple myeloma : a rational molecular target, file dfa8b995-895f-748b-e053-3a05fe0a3a96
|
143
|
|
An integrative genomic approach reveals coordinated expression of intronic miR-335, miR-342, and miR-561 with deregulated host genes in multiple myeloma, file dfa8b98f-7312-748b-e053-3a05fe0a3a96
|
142
|
|
lncRNA profiling in early-stage chronic lymphocytic leukemia identifies transcriptional fingerprints with relevance in clinical outcome, file dfa8b995-e015-748b-e053-3a05fe0a3a96
|
142
|
|
Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma, file dfa8b99d-8c7a-748b-e053-3a05fe0a3a96
|
142
|
|
Long Non-Coding RNAs in Multiple Myeloma, file dfa8b99a-2210-748b-e053-3a05fe0a3a96
|
140
|
|
The small GTPase RhoU lays downstream of JAK/STAT signaling and mediates cell migration in multiple myeloma, file dfa8b99a-b113-748b-e053-3a05fe0a3a96
|
139
|
|
Expanding the repertoire of miRNAs and miRNA-offset RNAs expressed in multiple myeloma by small RNA deep sequencing, file dfa8b99d-8c82-748b-e053-3a05fe0a3a96
|
138
|
|
Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo, file dfa8b995-313c-748b-e053-3a05fe0a3a96
|
134
|
|
A compendium of long non-coding RNAs transcriptional fingerprint in multiple myeloma, file dfa8b99b-84aa-748b-e053-3a05fe0a3a96
|
134
|
|
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases, file dfa8b9a5-9de4-748b-e053-3a05fe0a3a96
|
134
|
|
Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients, file dfa8b9a8-45a0-748b-e053-3a05fe0a3a96
|
127
|
|
Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma, file dfa8b999-ef47-748b-e053-3a05fe0a3a96
|
123
|
|
NEAT1 Long Isoform Is Highly Expressed in Chronic Lymphocytic Leukemia Irrespectively of Cytogenetic Groups or Clinical Outcomek, file dfa8b9a1-4020-748b-e053-3a05fe0a3a96
|
123
|
|
Transcriptomic analysis in multiple myeloma and primary plasma cell leukemia with t(11;14) reveals different expression patterns with biological implications in venetoclax sensitivity, file dfa8b9a8-6ecd-748b-e053-3a05fe0a3a96
|
123
|
|
Molecular classification and pharmacogenetics of primary plasma cell leukemia: an initial approach toward precision medicine, file dfa8b993-084f-748b-e053-3a05fe0a3a96
|
119
|
|
Heterogeneous expression of the collagen receptor DDR1 in chronic lymphocytic leukaemia and correlation with progression, file dfa8b997-1b7d-748b-e053-3a05fe0a3a96
|
117
|
|
Chronic lymphocytic leukemia cells impair osteoblastogenesis and promote osteoclastogenesis: role of TNFα, IL-6 and IL-11 cytokines, file dfa8b9a3-09f3-748b-e053-3a05fe0a3a96
|
117
|
|
Limits and Applications of Genomic Analysis of Circulating Tumor DNA as a Liquid Biopsy in Asymptomatic Forms of Multiple Myeloma, file dfa8b9a4-029d-748b-e053-3a05fe0a3a96
|
117
|
|
Mechanisms of immune evasion in multiple myeloma : Open questions and therapeutic opportunities, file dfa8b9a7-b769-748b-e053-3a05fe0a3a96
|
115
|
|
Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia, file dfa8b992-21e7-748b-e053-3a05fe0a3a96
|
113
|
|
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs, file dfa8b99f-b6ed-748b-e053-3a05fe0a3a96
|
110
|
|
Jagged ligands enhance the pro-angiogenic activity of multiple myeloma cells, file dfa8b9a3-a026-748b-e053-3a05fe0a3a96
|
109
|
|
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab, file dfa8b9a4-24d1-748b-e053-3a05fe0a3a96
|
108
|
|
Expression Pattern and Biological Significance of the lncRNA ST3GAL6-AS1 in Multiple Myeloma, file dfa8b9a1-ba8f-748b-e053-3a05fe0a3a96
|
104
|
|
Cancer Associated Fibroblasts and Senescent Thyroid Cells in the Invasive Front of Thyroid Carcinoma, file dfa8b9a0-a0c2-748b-e053-3a05fe0a3a96
|
103
|
|
Clonal evolution in therapy-related neoplasms, file dfa8b997-920c-748b-e053-3a05fe0a3a96
|
101
|
|
High rate of MRD-responses in young and fit patients with IGHV mutated chronic lymphocytic leukemia treated with front-line fludarabine, cyclophosphamide, and intensified dose of ofatumumab (FCO2), file dfa8b9a1-067b-748b-e053-3a05fe0a3a96
|
101
|
|
Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-mir-17-92, file dfa8b99c-0a25-748b-e053-3a05fe0a3a96
|
100
|
|
What Is New in the Treatment of Smoldering Multiple Myeloma?, file dfa8b9a5-741c-748b-e053-3a05fe0a3a96
|
100
|
|
The Non-Coding RNA Landscape of Plasma Cell Dyscrasias, file dfa8b9a1-369e-748b-e053-3a05fe0a3a96
|
98
|
|
ZNF521 Enhances MLL-AF9-Dependent Hematopoietic Stem Cell Transformation in Acute Myeloid Leukemias by Altering the Gene Expression Landscape, file dfa8b9a8-6ece-748b-e053-3a05fe0a3a96
|
98
|
|
Functional impact of genomic complexity on the transcriptome of Multiple Myeloma, file dfa8b9a8-5b8f-748b-e053-3a05fe0a3a96
|
93
|
|
Validation of the alternative international prognostic score-E (AIPS-E): analysis of binet stage a chronic lymphocytic patients enrolled into the O-CLL1-GISL protocol, file dfa8b9a6-27ef-748b-e053-3a05fe0a3a96
|
92
|
|
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients, file dfa8b9a4-0b03-748b-e053-3a05fe0a3a96
|
88
|
| Totale |
22.420 |